InflaRx NV (IFRX)

InflaRx Stock Analysis & Ratings

IFRX Stock Chart & Stats

Day’s Range$1.44 - $1.53
52-Week Range$1.31 - $5.69
Previous Close$1.44
Average Volume (3M)228.17K
Market Cap$66.31M
P/E Ratio-1.2
Next EarningsAug 04, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score4
EPS (TTM)-1.27



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was InflaRx’s price range in the past 12 months?
InflaRx lowest stock price was $1.31 and its highest was $5.68 in the past 12 months.
    What is InflaRx’s market cap?
    InflaRx’s market cap is $66.31M.
      What is InflaRx’s price target?
      The average price target for InflaRx is $5.00. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $7.00 ,the lowest forecast is $2.00. The average price target represents 233.33% Increase from the current price of $1.5.
        What do analysts say about InflaRx?
        InflaRx’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
          When is InflaRx’s upcoming earnings report date?
          InflaRx’s upcoming earnings report date is Aug 04, 2022 which is in 76 days.
            How were InflaRx’s earnings last quarter?
            InflaRx released its earnings results on May 12, 2022. The company reported -$0.338 earnings per share for the quarter, beating the consensus estimate of -$0.343 by $0.004.
              Is InflaRx overvalued?
              According to Wall Street analysts InflaRx’s price is currently Undervalued.
                Does InflaRx pay dividends?
                InflaRx does not currently pay dividends.
                What is InflaRx’s EPS estimate?
                InflaRx’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does InflaRx have?
                InflaRx has 44,200,000 shares outstanding.
                  What happened to InflaRx’s price movement after its last earnings report?
                  InflaRx reported an EPS of -$0.338 in its last earnings report, beating expectations of -$0.343. Following the earnings report the stock price went up 6.569%.
                    Which hedge fund is a major shareholder of InflaRx?
                    Currently, no hedge funds are holding shares in IFRX


                    InflaRx Stock Analysis

                    The InflaRx stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                    Learn more about TipRanks Smart Score

                    Company Description

                    InflaRx NV

                    InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products includes IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.

                    Similar Stocks
                    Price & Change
                    Sg Blocks
                    Forte Biosciences
                    Solid Biosciences
                    Leap Therapeutics

                    Popular Stocks

                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis